JWA
ZVRA icon

JFS Wealth Advisors’s Zevra Therapeutics ZVRA Stock Holding History

JFS Wealth Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29 Hold
2
– – ﹤0.01% 2238
2026
Q1 		$19 Hold
2
– – ﹤0.01% 1872
2025
Q4 		$18 Hold
2
– – ﹤0.01% 1911
2025
Q3 		$20 Hold
2
– – ﹤0.01% 1890
2025
Q2 		$18 Hold
2
– – ﹤0.01% 1855
2025
Q1 		$15 Hold
2
– – ﹤0.01% 1925
2024
Q4 		$17 Hold
2
– – ﹤0.01% 1934
2024
Q3 		$14 Hold
2
– – ﹤0.01% 1955
2024
Q2 		$10 Hold
2
– – ﹤0.01% 1980
2024
Q1 		$12 Hold
2
– – ﹤0.01% 2002
2023
Q4 		$14 Buy
+2
New +$9 ﹤0.01% 1992

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JFS Wealth Advisors's ZVRA Position: Q2 2026 in Review

JFS Wealth Advisors held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 2 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

JFS Wealth Advisors first reported a position in ZVRA in Q4 2023 and has held it in 11 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • JFS Wealth Advisors held 2 shares of Zevra Therapeutics worth $29 as of Q2 2026.
  • JFS Wealth Advisors left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #2238 holding.
  • JFS Wealth Advisors first reported a position in Zevra Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.